Paulo Jose Martins Bispo, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endophthalmitis | 15 | 2023 | 263 | 3.150 |
Why?
|
Eye Infections, Bacterial | 14 | 2023 | 239 | 3.120 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 8 | 2024 | 705 | 2.570 |
Why?
|
Keratitis | 8 | 2023 | 239 | 2.400 |
Why?
|
Eye Infections | 4 | 2023 | 63 | 2.140 |
Why?
|
Microbial Sensitivity Tests | 19 | 2024 | 1971 | 2.050 |
Why?
|
Staphylococcal Infections | 10 | 2024 | 1393 | 1.940 |
Why?
|
Eye Infections, Fungal | 5 | 2023 | 99 | 1.750 |
Why?
|
Corneal Ulcer | 6 | 2023 | 125 | 1.670 |
Why?
|
Anti-Bacterial Agents | 23 | 2024 | 7478 | 1.110 |
Why?
|
RNA, Ribosomal, 16S | 7 | 2024 | 1043 | 1.040 |
Why?
|
Lincosamides | 1 | 2024 | 5 | 0.950 |
Why?
|
DNA, Bacterial | 7 | 2023 | 1477 | 0.940 |
Why?
|
Staphylococcus epidermidis | 3 | 2014 | 121 | 0.870 |
Why?
|
Treponema pallidum | 1 | 2023 | 48 | 0.860 |
Why?
|
Anti-Infective Agents | 3 | 2024 | 986 | 0.820 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2024 | 592 | 0.770 |
Why?
|
Achromobacter | 1 | 2021 | 8 | 0.740 |
Why?
|
Conjunctivitis | 2 | 2022 | 153 | 0.730 |
Why?
|
Aqueous Humor | 4 | 2016 | 152 | 0.730 |
Why?
|
Polymerase Chain Reaction | 8 | 2023 | 6069 | 0.720 |
Why?
|
Drug Resistance, Bacterial | 10 | 2024 | 1069 | 0.710 |
Why?
|
Syphilis | 1 | 2023 | 243 | 0.710 |
Why?
|
Uveitis | 3 | 2020 | 398 | 0.700 |
Why?
|
Organ Preservation Solutions | 1 | 2021 | 105 | 0.690 |
Why?
|
Epithelium, Corneal | 1 | 2022 | 246 | 0.670 |
Why?
|
Drug Contamination | 1 | 2021 | 152 | 0.660 |
Why?
|
Vitreous Body | 4 | 2016 | 400 | 0.650 |
Why?
|
Ophthalmic Solutions | 1 | 2021 | 312 | 0.650 |
Why?
|
Fluoroquinolones | 3 | 2024 | 307 | 0.640 |
Why?
|
Limbus Corneae | 1 | 2021 | 144 | 0.640 |
Why?
|
Bacteria | 9 | 2023 | 2209 | 0.590 |
Why?
|
Eye Infections, Parasitic | 1 | 2018 | 27 | 0.580 |
Why?
|
Eye Infections, Viral | 1 | 2018 | 61 | 0.560 |
Why?
|
Cross Infection | 5 | 2020 | 1427 | 0.550 |
Why?
|
Staphylococcus | 3 | 2024 | 145 | 0.440 |
Why?
|
Antifungal Agents | 3 | 2023 | 769 | 0.410 |
Why?
|
Aza Compounds | 1 | 2012 | 34 | 0.400 |
Why?
|
Blepharitis | 1 | 2012 | 37 | 0.390 |
Why?
|
Gentian Violet | 2 | 2011 | 25 | 0.390 |
Why?
|
Phenazines | 2 | 2011 | 53 | 0.380 |
Why?
|
Macrolides | 2 | 2024 | 204 | 0.380 |
Why?
|
Gram-Positive Bacteria | 2 | 2011 | 180 | 0.370 |
Why?
|
Multilocus Sequence Typing | 4 | 2020 | 102 | 0.350 |
Why?
|
Gram-Negative Bacteria | 2 | 2011 | 275 | 0.350 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2921 | 0.340 |
Why?
|
Oxazolidinones | 2 | 2020 | 99 | 0.330 |
Why?
|
Candida albicans | 3 | 2022 | 377 | 0.330 |
Why?
|
Molecular Typing | 2 | 2023 | 115 | 0.300 |
Why?
|
Keratoplasty, Penetrating | 3 | 2021 | 143 | 0.300 |
Why?
|
Mycobacterium chelonae | 1 | 2018 | 12 | 0.300 |
Why?
|
Bacterial Typing Techniques | 4 | 2023 | 263 | 0.290 |
Why?
|
Bacteriological Techniques | 4 | 2021 | 276 | 0.280 |
Why?
|
Molecular Epidemiology | 2 | 2023 | 471 | 0.280 |
Why?
|
Water Microbiology | 1 | 2018 | 116 | 0.280 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2018 | 81 | 0.270 |
Why?
|
Biofilms | 2 | 2016 | 641 | 0.270 |
Why?
|
Quinolines | 1 | 2012 | 769 | 0.270 |
Why?
|
Herpesvirus 3, Human | 2 | 2018 | 159 | 0.260 |
Why?
|
Cataract Extraction | 2 | 2016 | 464 | 0.260 |
Why?
|
Herpesvirus 2, Human | 2 | 2018 | 191 | 0.260 |
Why?
|
Staphylococcus aureus | 3 | 2024 | 1424 | 0.250 |
Why?
|
Streptococcus pneumoniae | 3 | 2022 | 762 | 0.240 |
Why?
|
Oxepins | 1 | 2024 | 3 | 0.240 |
Why?
|
Lenses, Intraocular | 1 | 2016 | 141 | 0.230 |
Why?
|
Dexamethasone | 1 | 2012 | 1963 | 0.230 |
Why?
|
Lens Implantation, Intraocular | 1 | 2016 | 192 | 0.230 |
Why?
|
DNA, Ribosomal | 2 | 2021 | 300 | 0.230 |
Why?
|
Brazil | 9 | 2021 | 1248 | 0.210 |
Why?
|
Streptococcus | 1 | 2024 | 197 | 0.210 |
Why?
|
Candida tropicalis | 1 | 2022 | 6 | 0.210 |
Why?
|
Amphotericin B | 1 | 2023 | 140 | 0.200 |
Why?
|
Glucocorticoids | 1 | 2012 | 2132 | 0.200 |
Why?
|
Azithromycin | 1 | 2024 | 201 | 0.200 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2023 | 766 | 0.200 |
Why?
|
Vancomycin | 2 | 2022 | 504 | 0.200 |
Why?
|
Enterococcus faecalis | 2 | 2020 | 244 | 0.190 |
Why?
|
Bacteremia | 3 | 2015 | 989 | 0.190 |
Why?
|
Mouth | 1 | 2024 | 381 | 0.190 |
Why?
|
Otitis Media with Effusion | 1 | 2023 | 115 | 0.190 |
Why?
|
Herpesvirus 1, Human | 2 | 2018 | 743 | 0.190 |
Why?
|
Yeasts | 1 | 2022 | 278 | 0.190 |
Why?
|
Methyltransferases | 1 | 2024 | 371 | 0.190 |
Why?
|
Toxoplasmosis, Ocular | 2 | 2019 | 28 | 0.190 |
Why?
|
Bacterial Infections | 3 | 2019 | 1387 | 0.190 |
Why?
|
Corynebacterium Infections | 1 | 2021 | 27 | 0.190 |
Why?
|
Cornea | 2 | 2020 | 1316 | 0.180 |
Why?
|
Humans | 46 | 2024 | 765968 | 0.180 |
Why?
|
Eye Banks | 1 | 2021 | 40 | 0.180 |
Why?
|
Fusarium | 1 | 2020 | 50 | 0.180 |
Why?
|
Sensitivity and Specificity | 5 | 2023 | 14652 | 0.170 |
Why?
|
Staphylococcal Skin Infections | 1 | 2021 | 77 | 0.170 |
Why?
|
Vaccines, Conjugate | 1 | 2022 | 334 | 0.170 |
Why?
|
Toxoplasma | 2 | 2019 | 158 | 0.170 |
Why?
|
Metagenomics | 2 | 2020 | 473 | 0.170 |
Why?
|
Enterococcus faecium | 1 | 2020 | 101 | 0.170 |
Why?
|
Community-Acquired Infections | 2 | 2021 | 470 | 0.160 |
Why?
|
Aspergillus fumigatus | 1 | 2020 | 158 | 0.160 |
Why?
|
Povidone-Iodine | 1 | 2019 | 54 | 0.160 |
Why?
|
Neglected Diseases | 1 | 2019 | 67 | 0.160 |
Why?
|
Soft Tissue Infections | 1 | 2021 | 167 | 0.160 |
Why?
|
Middle Aged | 17 | 2024 | 223009 | 0.160 |
Why?
|
Massachusetts | 2 | 2023 | 8875 | 0.150 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2021 | 231 | 0.150 |
Why?
|
Inflammasomes | 1 | 2023 | 543 | 0.150 |
Why?
|
Disease Outbreaks | 1 | 2018 | 1759 | 0.150 |
Why?
|
Pneumococcal Vaccines | 1 | 2022 | 414 | 0.150 |
Why?
|
Polymyxin B | 2 | 2020 | 43 | 0.150 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2020 | 339 | 0.150 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2018 | 96 | 0.140 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2018 | 37 | 0.140 |
Why?
|
Tissue and Organ Harvesting | 1 | 2021 | 373 | 0.140 |
Why?
|
Keratitis, Dendritic | 1 | 2017 | 18 | 0.140 |
Why?
|
Tissue Donors | 3 | 2021 | 2395 | 0.130 |
Why?
|
Genotype | 3 | 2023 | 13024 | 0.130 |
Why?
|
Male | 19 | 2024 | 363698 | 0.120 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 644 | 0.120 |
Why?
|
Drug Combinations | 3 | 2021 | 2077 | 0.120 |
Why?
|
Adult | 13 | 2024 | 223044 | 0.120 |
Why?
|
Sequence Analysis, DNA | 2 | 2023 | 4772 | 0.120 |
Why?
|
Hospitals | 3 | 2020 | 3888 | 0.120 |
Why?
|
Genes, Bacterial | 2 | 2020 | 1077 | 0.120 |
Why?
|
Conjunctivitis, Bacterial | 1 | 2014 | 22 | 0.120 |
Why?
|
Candidemia | 1 | 2015 | 46 | 0.120 |
Why?
|
Herpes Simplex | 1 | 2018 | 472 | 0.110 |
Why?
|
Aged | 13 | 2024 | 171117 | 0.110 |
Why?
|
DNA Topoisomerase IV | 1 | 2013 | 42 | 0.110 |
Why?
|
DNA Primers | 1 | 2018 | 2825 | 0.110 |
Why?
|
DNA, Fungal | 1 | 2014 | 276 | 0.110 |
Why?
|
Mycobacterium Infections | 1 | 2014 | 123 | 0.110 |
Why?
|
Cytomegalovirus | 1 | 2018 | 751 | 0.110 |
Why?
|
Methicillin Resistance | 1 | 2014 | 198 | 0.100 |
Why?
|
DNA Gyrase | 1 | 2013 | 86 | 0.100 |
Why?
|
Female | 16 | 2024 | 396112 | 0.100 |
Why?
|
Mycobacterium | 1 | 2014 | 253 | 0.100 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 2 | 2018 | 142 | 0.100 |
Why?
|
Fungi | 1 | 2014 | 348 | 0.090 |
Why?
|
Cations | 1 | 2012 | 240 | 0.090 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2013 | 239 | 0.090 |
Why?
|
Cytomegalovirus Infections | 1 | 2018 | 836 | 0.090 |
Why?
|
Bacterial Proteins | 1 | 2024 | 3837 | 0.090 |
Why?
|
Trimethoprim | 2 | 2021 | 79 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3655 | 0.090 |
Why?
|
Pseudomonas Infections | 2 | 2015 | 622 | 0.090 |
Why?
|
Culture Media | 1 | 2012 | 890 | 0.080 |
Why?
|
Pneumococcal Infections | 1 | 2014 | 527 | 0.080 |
Why?
|
Phacoemulsification | 1 | 2011 | 151 | 0.080 |
Why?
|
Plasmids | 1 | 2014 | 2274 | 0.080 |
Why?
|
Drug Resistance | 1 | 2014 | 1591 | 0.070 |
Why?
|
Lasers, Excimer | 1 | 2018 | 68 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5929 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 2 | 2012 | 1276 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2024 | 22223 | 0.070 |
Why?
|
Aged, 80 and over | 7 | 2018 | 59489 | 0.070 |
Why?
|
Lens Capsule, Crystalline | 1 | 2016 | 38 | 0.070 |
Why?
|
Pseudophakia | 1 | 2016 | 60 | 0.060 |
Why?
|
Swine | 3 | 2020 | 5988 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2011 | 560 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2023 | 81514 | 0.060 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2016 | 939 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2589 | 0.060 |
Why?
|
Toll-Like Receptor 1 | 1 | 2023 | 48 | 0.060 |
Why?
|
Caspase 1 | 1 | 2023 | 227 | 0.050 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2008 | 1141 | 0.050 |
Why?
|
Middle Ear Ventilation | 1 | 2023 | 101 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2011 | 1543 | 0.050 |
Why?
|
Polymyxins | 1 | 2021 | 17 | 0.050 |
Why?
|
Toll-Like Receptor 2 | 1 | 2023 | 348 | 0.050 |
Why?
|
Corynebacterium | 1 | 2021 | 49 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4562 | 0.050 |
Why?
|
Benzalkonium Compounds | 1 | 2020 | 22 | 0.050 |
Why?
|
Ear, Middle | 1 | 2023 | 341 | 0.040 |
Why?
|
Contact Lenses, Hydrophilic | 1 | 2020 | 53 | 0.040 |
Why?
|
Goblet Cells | 1 | 2023 | 301 | 0.040 |
Why?
|
Argentina | 1 | 2021 | 249 | 0.040 |
Why?
|
Eye Evisceration | 1 | 2019 | 21 | 0.040 |
Why?
|
Onchocerciasis, Ocular | 1 | 2019 | 7 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3797 | 0.040 |
Why?
|
Trachoma | 1 | 2019 | 19 | 0.040 |
Why?
|
Eye Enucleation | 1 | 2019 | 128 | 0.040 |
Why?
|
Corneal Perforation | 1 | 2019 | 28 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20124 | 0.040 |
Why?
|
Latin America | 1 | 2021 | 416 | 0.040 |
Why?
|
Leprosy | 1 | 2019 | 125 | 0.040 |
Why?
|
Young Adult | 5 | 2018 | 59889 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 14071 | 0.040 |
Why?
|
Adolescent | 6 | 2018 | 88835 | 0.040 |
Why?
|
Herpesviridae | 1 | 2019 | 104 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2012 | 12437 | 0.040 |
Why?
|
Animals | 4 | 2022 | 168764 | 0.040 |
Why?
|
Herpesviridae Infections | 1 | 2019 | 268 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2023 | 1028 | 0.040 |
Why?
|
Prostheses and Implants | 1 | 2023 | 1273 | 0.030 |
Why?
|
DNA Probes | 1 | 2017 | 541 | 0.030 |
Why?
|
Phylogeography | 1 | 2014 | 71 | 0.030 |
Why?
|
RNA, Ribosomal, 18S | 1 | 2014 | 54 | 0.030 |
Why?
|
Fungemia | 1 | 2015 | 57 | 0.030 |
Why?
|
Acinetobacter Infections | 1 | 2015 | 74 | 0.030 |
Why?
|
Sepsis | 1 | 2008 | 2606 | 0.030 |
Why?
|
Adhesins, Bacterial | 1 | 2014 | 118 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 2014 | 326 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2014 | 136 | 0.030 |
Why?
|
Bacterial Capsules | 1 | 2014 | 246 | 0.030 |
Why?
|
Klebsiella Infections | 1 | 2015 | 146 | 0.030 |
Why?
|
Klebsiella | 1 | 2013 | 49 | 0.030 |
Why?
|
Acinetobacter | 1 | 2013 | 39 | 0.030 |
Why?
|
Agar | 1 | 2012 | 51 | 0.020 |
Why?
|
DNA, Viral | 1 | 2019 | 2199 | 0.020 |
Why?
|
Multigene Family | 1 | 2014 | 1080 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2019 | 874 | 0.020 |
Why?
|
Virulence Factors | 1 | 2014 | 500 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 2015 | 519 | 0.020 |
Why?
|
Acinetobacter baumannii | 1 | 2012 | 125 | 0.020 |
Why?
|
Gene Amplification | 1 | 2014 | 1091 | 0.020 |
Why?
|
Genome, Bacterial | 1 | 2014 | 797 | 0.020 |
Why?
|
Prospective Studies | 4 | 2017 | 54802 | 0.020 |
Why?
|
Child | 5 | 2017 | 80564 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2015 | 26346 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15747 | 0.020 |
Why?
|
Hospitals, University | 1 | 2010 | 574 | 0.020 |
Why?
|
RNA, Ribosomal | 1 | 2008 | 227 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2208 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5020 | 0.020 |
Why?
|
Phylogeny | 1 | 2014 | 2832 | 0.020 |
Why?
|
Developing Countries | 1 | 2019 | 2911 | 0.020 |
Why?
|
Infant | 3 | 2015 | 36386 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9347 | 0.020 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2013 | 855 | 0.020 |
Why?
|
Child, Preschool | 3 | 2015 | 42500 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2008 | 955 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1275 | 0.010 |
Why?
|
Genetic Variation | 1 | 2018 | 6610 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3620 | 0.010 |
Why?
|
Escherichia coli | 1 | 2014 | 4214 | 0.010 |
Why?
|
Visual Acuity | 1 | 2011 | 2708 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10070 | 0.010 |
Why?
|
United States | 2 | 2020 | 72903 | 0.010 |
Why?
|
Risk Factors | 2 | 2019 | 74840 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39193 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 26318 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15842 | 0.010 |
Why?
|
Incidence | 1 | 2010 | 21480 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2010 | 65188 | 0.000 |
Why?
|